Marshall Wace, LLP Gilead Sciences, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,023,665 shares of GILD stock, worth $94 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

1,023,665

Previous 120,516 749.4%

Holding current value

$94 Million

Previous $8.27 Million 937.77%

% of portfolio

0.11%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $60.1 Million - $75.9 Million	903,149 Added 749.4%	1,023,665 $85.8 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $7.61 Million - $8.78 Million	120,516 New	120,516 $8.27 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $383 Million - $437 Million	-5,035,412 Reduced 99.23%	39,190 $3.02 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $49.8 Million - $56.8 Million	644,672 Added 14.55%	5,074,602 $421 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $66.4 Million - $95.3 Million	1,064,987 Added 31.65%	4,429,930 $380 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $22.7 Million - $25.9 Million	381,493 Added 12.79%	3,364,943 $208 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $28.5 Million - $32.1 Million	493,011 Added 19.8%	2,983,450 $184 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $143 Million - $179 Million	2,462,555 Added 8831.43%	2,490,439 $148 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $1.19 Million - $1.35 Million	18,284 Added 190.46%	27,884 $2.03 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $7.75 Million - $8.36 Million	-114,496 Reduced 92.26%	9,600 $671,000
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $4.8 Million - $5.25 Million	75,637 Added 156.08%	124,096 $8.55 Million
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $2.45 Million - $2.8 Million	-40,867 Reduced 45.75%	48,459 $3.13 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $5.06 Million - $5.77 Million	89,326 New	89,326 $5.2 Million
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $274,819 - $319,116	-3,799 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $28.4 Million - $36.3 Million	-452,954 Reduced 99.17%	3,799 $284,000
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $31.4 Million - $34.6 Million	-510,190 Reduced 52.76%	456,753 $29.7 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $19.2 Million - $21.2 Million	307,406 Added 46.61%	966,943 $61.3 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $40.8 Million - $45.8 Million	659,537 New	659,537 $44.6 Million
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $7.69 Million - $8.62 Million	-123,013 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $8.13 Million - $10.6 Million	-134,351 Reduced 52.2%	123,013 $7.7 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $17.2 Million - $19.1 Million	241,875 Added 1561.59%	257,364 $19.9 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $12 Million - $14 Million	-185,098 Reduced 92.28%	15,489 $1.1 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $14.6 Million - $17.8 Million	200,587 New	200,587 $15.1 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $1.25 Million - $1.47 Million	-17,562 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $1.27 Million - $1.5 Million	17,562	17,562 $1.42 Million

Others Institutions Holding GILD

# of Institutions

1,941

Shares Held

989M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $115B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Gilead Sciences, Inc. Transaction History